Literature DB >> 21806078

Prevalence of 'borderline' values of cardiovascular risk factors in the clinical practice of general medicine in Italy: results of the BORDERLINE study.

Giuliano Tocci1, Andrea Ferrucci, Jasmine Passerini, Maurizio Averna, Paolo Bellotti, Graziella Bruno, Francesco Cosentino, Gaetano Crepaldi, Cristina Giannattasio, Maria Grazia Modena, Giulio Nati, Antonio Tiengo, Bruno Trimarco, Diego Vanuzzo, Massimo Volpe.   

Abstract

INTRODUCTION: The prevalence of patients with 'borderline' levels of cardiovascular risk factors has been rarely investigated, being often reported in studies evaluating abnormal values of these parameters. The BORDERLINE study represents a pilot experience to primarily identify the prevalence of 'high-normal' conditions, such as pre-hypertension, lipid and glucose levels in the upper range of normality in the setting of general practice in Italy. AIM: The aim of this study was to evaluate the prevalence of patients with 'borderline' values of cardiovascular risk factors in Italy.
METHODS: Involved physicians were asked to evaluate the first 20 outpatients, consecutively seen in June 2009. Data were collected in a study-designed case-report form, in which physicians identified thresholds rather than reported absolute values of several clinical parameters. High-normal values were defined as follows: blood pressure (BP) 130-140/85-90 mmHg; total cholesterol 180-200 mg/dL; low-density lipoprotein cholesterol (LDL-C) 130-150 mg/dL; high-density lipoprotein cholesterol (HDL-C) 30-40 mg/dL in males and 40-50 mg/dL in females; triglycerides 130-150 mg/dL and fasting glucose 100-110 mg/dL.
RESULTS: Fifty-three Italian physicians provided valuable clinical data on 826 individual outpatients, among which 692 (83.7%, 377 women, mean age 60.9 ± 13.2 years, body mass index 26.6 ± 5.0 kg/m2) were included in the present analysis. Prevalence of borderline values of systolic BP and total cholesterol levels were at least comparable with those in the normal limits of the corresponding parameters, whereas prevalence of borderline diastolic BP, LDL-C, HDL-C, triglycerides and fasting glucose levels was significantly lower than that of normal values, but higher than that of abnormal values of the corresponding parameters.
CONCLUSIONS: Using this sample of healthy subjects in the setting of general practice in Italy, our results demonstrated a relatively high prevalence of borderline values of cardiovascular risk factors, which was at least comparable with that of normal, but significantly higher than that of abnormal thresholds. These preliminary findings may prompt more extensive investigations in the area of 'borderline' cardiovascular risk. This information may, in fact, potentially enable the design of more effective prevention strategies in the future to limit the burden of cardiovascular disease in the general population in Italy. Received for publication 4 March 2011; accepted for publication 20 April 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21806078     DOI: 10.2165/11593420-000000000-00000

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  25 in total

Review 1.  Revisiting Rose: strategies for reducing coronary heart disease.

Authors:  Douglas G Manuel; Jenny Lim; Peter Tanuseputro; Geoffrey M Anderson; David A Alter; Andreas Laupacis; Cameron A Mustard
Journal:  BMJ       Date:  2006-03-18

2.  European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

3.  Managing cardiovascular risk: the need for change.

Authors:  M Volpe; L R W Erhardt; B Williams
Journal:  J Hum Hypertens       Date:  2007-09-13       Impact factor: 3.012

4.  Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe.

Authors:  Jonathan Morrell; Uwe Zeymer; Iris Baumgartner; Tobias Limbourg; Joachim Röther; Deepak L Bhatt; Ph Gabriel Steg
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2011-04

5.  Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors.

Authors:  K Landin; L Tengborn; U Smith
Journal:  J Intern Med       Date:  1991-02       Impact factor: 8.989

6.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

7.  Blood pressure control in Italy: results of recent surveys on hypertension.

Authors:  Massimo Volpe; Giuliano Tocci; Bruno Trimarco; Enrico Agabiti Rosei; Claudio Borghi; Ettore Ambrosioni; Alessandro Menotti; Alberto Zanchetti; Giuseppe Mancia
Journal:  J Hypertens       Date:  2007-07       Impact factor: 4.844

8.  Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.

Authors:  Ozgur Bahadir; Mehmet Uzunlulu; Aytekin Oguz; Muzeyyen A Bahadir
Journal:  Hypertens Res       Date:  2007-01       Impact factor: 3.872

9.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

Review 10.  Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies.

Authors:  Hertzel C Gerstein; Pasqualina Santaguida; Parminder Raina; Katherine M Morrison; Cynthia Balion; Dereck Hunt; Hossein Yazdi; Lynda Booker
Journal:  Diabetes Res Clin Pract       Date:  2007-06-29       Impact factor: 5.602

View more
  3 in total

1.  Prevalence of metabolic syndrome in the clinical practice of general medicine in Italy.

Authors:  Giuliano Tocci; Andrea Ferrucci; Graziella Bruno; Elmo Mannarino; Giulio Nati; Bruno Trimarco; Massimo Volpe
Journal:  Cardiovasc Diagn Ther       Date:  2015-08

2.  Prevalence and Correlates of Prehypertension Among Adults in Urban South India.

Authors:  Prasanna Mithra Parthaje; Bhaskaran Unnikrishnan; Kavumpurathu Raman Thankappan; Rekha Thapar; Quek Kia Fatt; Brian Oldenburg
Journal:  Asia Pac J Public Health       Date:  2015-11-22       Impact factor: 1.399

3.  Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database.

Authors:  Vivianne Presta; Ilaria Figliuzzi; Barbara Citoni; Francesca Miceli; Allegra Battistoni; Maria Beatrice Musumeci; Roberta Coluccia; Luciano De Biase; Andrea Ferrucci; Massimo Volpe; Giuliano Tocci
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-23       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.